498 results on '"Perol, M."'
Search Results
202. Évaluation d’une fiche d’aide à la décision en cas d’aggravation d’un patient cancéreux
203. PCN153 - Cost-Effectiveness Analysis of Afatinib Versus Gefitinib in Egfr-Mutated Population with Advanced Non-Small-Cell Lung Cancer in France
204. E3 - Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC)
205. 1 - Longitudinal circulating-tumor DNA profiling of EGFR-mutated lung adenocarcinoma patients treated with EGFR-tyrosine kinase inhibitors
206. 1298O_PR - Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study
207. 1309P - Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
208. 120P - Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)
209. Efficacité du bévacizumab associé à un doublet de chimiothérapie à base de sels de platine en première ligne de traitement des cancers du poumon ALK-réarrangés : analyse des données de l’étude IFCT-1302 CLINALK
210. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy
211. Randomised, Multicentre, Phase Iii, Open-Label Study of Alectinib Vs Crizotinib in Treatment-Naïve Anaplastic Lymphoma Kinase (Alk)-Positive Advanced Nsclc (Alex Study)
212. Quality of Life (Qol) Results from the Phase 3 Revel Study of Ramucirumab + Docetaxel (Ram + Dtx) Versus Placebo + Docetaxel (Pl + Dtx) in Advanced/Metastatic Nsclc Patients (Pts) with Progression After Platinum Based Chemotherapy
213. Retrospective Multicenter Study in Non Small Cell Lung Cancer (Nsclc) Patients with Epidermal Growth Factor Receptor (Egfr) Activating Mutation Treated First-Line Tyrosine Kinase Inhibitor (Tki): Evaluation of Progression According to Recist, Therapeutic Approach and Its Effect
214. Ramucirumab Improves Survival in Stage IV NSCLC
215. Validation des critères RECIST chez des patients porteurs d’un cancer bronchique traités par chimiothérapie
216. Chimiothérapie (CT) de maintenance par bevacizumab/pemetrexed chez des patients (pts) avec un cancer bronchique non à petites cellules non épidermoïdes (CBNPCne) avancé : survie globale actualisée de l’essai randomisé de phase III AVAPERL
217. Réirradiation des tumeurs thoraciques par CyberKnife® : faisabilité et tolérance
218. Psoriasis induits par les chimiothérapies anti-PD1
219. PCN147 - Is the Integrated Electronic Health Record Cost-Effective for a Cancer Consultation? Results from the E-SI (PREPS-SIPS) Study
220. 1296TiP - A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)
221. 1244P - French real-life efficacy of 1st line gefitinib in EGFR mutation-positive NSCLC in the prospective EPIDAURE study: Results by EGFR exon 19 Del and L858R mutation subtypes
222. 1234P - Osimertinib in EGFR T790M positive advanced NSCLC (aNSCLC) – real–life data from the French temporary authorization for use (ATU) program
223. Ré-irradiation des tumeurs thoraciques par CyberKnife® : faisabilité et tolérance
224. Efficacité du pemetrexed en 2e ligne dans les CBNPC avancé après un intervalle libre ou un traitement de maintenance par gemcitabine ou erlotinib dans l’étude IFCT-GFPC 05-02
225. PCN308 - Cost of Questionnaire-Based Process to Identify Occupational Exposures Among Patients with Lung Cancer
226. Phase II Study of Bevacizumab in Combination with 1st-Line Chemotherapy or 2nd-Line Erlotinib in Non-Squamous Nsclc (Ns-Nsclc) Patients with Asymptomatic Untreated Brain Metastases (ML21823)
227. Cost-Utility Analysis of Maintenance Therapy with Either Gemcitabine or Erlotinib versus Observation with Predefined Second-Line Treatment after Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Nsclc: Ifct-Gfpc 0502-ECO Phase III Study
228. Embolie gazeuse de révélation tardive après ponction transpariétale pulmonaire
229. 9005 ORAL Is There a Benefit to Maintenance Therapy After First Line Chemotherapy in Advanced Non-small Cell Lung Cancer – a Systematic Review With Meta-analysis
230. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.
231. P.243 Efficacité de l’association gemcitabine-oxaliplatine (GEMOX) dans les carcinomes (neuro)endocrines bien différenciés localement avancés ou métastatiques
232. L’hyperplasie neuroendocrine pulmonaire idiopathique : une lésion prénéoplasique méconnue
233. Épanchement pleural gauche massif révélateur d’une péricardite constrictive idiopathique
234. Comment traiter la rechute du CBNPC après une chirurgie et chimiothérapie ?
235. An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study
236. IFCT0401-bio trial: Predictive biological markers for disease control (DC) of patients with non-resectable, adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib
237. 192 Radiothérapie monofractionnée et chimiothérapie concomitante dans le traitement du carcinome à petites cellules (CPC) limité au thorax
238. 269 Oncologie thoracique orpheline : carcinomes pléiomorphes, sarcomatoïdes, ou avec éléments sarcomateux
239. Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.
240. P1-135 - Traitement par octréotide marqué à l’indium 111 : l’expérience lyonnaise
241. IFCT0401-bio trial: Pathological and EGF-r molecular analysis of tumor-biopsy samples from patients with non-resectable, pneumonic-type adenocarcinoma (P-ADC) treated by gefinitib. Preliminary results from surgical specimens
242. Improvement in anemia management with epoietin alfa (EA) in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC) (GFPC 0202)
243. PCN61 - Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors
244. Interet de l’IRM corps entier dans le bilan d’extension metastatique
245. P-941 Phase II study of gefitinib (IRESSA) administered as first linetreatment in patients with non-resectable, pneumonic-type adenocarcinoma (P-ADC)
246. P-320 Gefitinib therapy of advanced non small-cell lung cancer (NSCLC): A Markov model-based economic analysis
247. P-479 Expression of class III beta tubulin is predictive of patientoutcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy
248. O-091 A randomized phase II trial of docetaxel alone and in combinationwith gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer
249. Early variations of circulating IL-6 and IL-10 during thoracic irradiation are predictive for incidence of radiation pneumonitis in patients with non small cell lung cancer: Results from a prospective study
250. Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.